<DOC>
	<DOCNO>NCT01907230</DOCNO>
	<brief_summary>Antiviral prophylaxis prevent risk biologic agents-associated HBV reactivation hepatitis B inactive carrier patient past HBV infection</brief_summary>
	<brief_title>Entecavir Biological Agents Associated HBV Reactivation Inflammatory Arthritis Patients</brief_title>
	<detailed_description>The risk HBV reactivation associate intensity immunosuppression . Biological therapy block action biological product involve immune-inflammatory pathogenesis many disease . However , biologic agent induce profound immunosuppression , use report associated HBV reactivation . Currently , actual incidence HBV reactivation inflammatory arthritis patient underwent biologic treatment ( TNF-α blockade ) unclear , especially inflammatory arthritis ( IA ) patient past hepatitis B infection . In study , plan enroll IA patient inactive HBV carrier ( HBsAg-positive/ HBV viral load &lt; 2000 IU/ml ; subgroup 1 ) , past HBV infection ( HBsAg-negative/anti-HBc-positive/ HBV viral load &lt; 2000 IU/ml ; subgroup 2 ) ; first line biologic treatment ( Humira Enbrel Simponi Orencia Mabthera Actemra ) indicate . Patients randomize 1:1 ratio receive either prophylactic therapeutic entecavir treatment subgroup . In prophylactic group , participant initiate entecavir 0.5 mg/day orally one week biologic treatment . Entecavir treatment continue normally 12 month . In therapeutic group , patient start entecavir therapy , 0.5 mg/day orally , reactivation HBV ( pre-emptive treatment ) . HBV reactivation define detectable HBV viral load 2 consecutive visit one month apart . The main goal study delineate incidence HBV reactivation biologic treatment IA patient inactive HBV carrier past HBV infection , try define optimal HBV monitoring antiviral prophylactic strategy IA patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Age : 20 90 y/o . 2 . HBsAgpositive 6 month HBV DNA &lt; 2000 IU/ml ( Subgroup 1）or HBsAgnegative antiHBc positive HBV DNA &lt; 2000 IU/ml ( Subgroup 2） . 3 . Inflammatory arthritis patient plan treat biological agent , include Humira Enbrel Simponi Orencia Mabthera Actemra ; first line biologic treatment indicate . 1 . HCV , HIV , HDV coinfection . 2 . HCC malignancy within 3 year . 3 . Decompensated liver cirrhosis ( CTP score ≥ 7 ) . 4 . Uremia patient hemodialysis continuous ambulatory peritoneal dialysis patient Ccr &lt; 50 mL/min 5 . Pregnant breastfeed woman . 6 . Women childbearing potential ( WOCBP ) unwilling unable use acceptable method contraception avoid pregnancy throughout study 4 week last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Inactive HBV carrier</keyword>
	<keyword>Resolved Hepatitis B</keyword>
	<keyword>HBV reactivation</keyword>
	<keyword>Anti-tumor necrotic factor-alfa</keyword>
</DOC>